We are live on ! Find out more
AGP

Artia Global Partners Portfolio holdings

AUM $499M
1-Year Est. Return 186.05%
This Fund
S&P 500
This Quarter Est. Return
+17.75%
1 Year Est. Return
+186.05%
3 Year Est. Return
+672.09%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$395M
AUM Growth
+$115M
Cap. Flow
+$86.6M
Cap. Flow %
21.93%
Top 10 Hldgs %
76.35%
Holding
48
New
11
Increased
6
Reduced
8
Closed
13

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$79M
2
VRNA
Verona Pharma
VRNA
+$16.9M
3
BSX icon
Boston Scientific
BSX
+$13.1M
4
INSM icon
Insmed
INSM
+$11.5M
5
DGX icon
Quest Diagnostics
DGX
+$9.32M

Top Sells

Rank Stock Value
1
NVO
Novo Nordisk
NVO
+$17.2M
2
PCVX icon
Vaxcyte
PCVX
+$13.3M
3
NUVL
Nuvalent
NUVL
+$8.86M
4
RVMD icon
Revolution Medicines
RVMD
+$7.31M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$7.14M

Sector Composition

Rank Sector Weight
1 Healthcare 86.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLY icon
1
Eli Lilly
LLY
$1.07T
$78.4M 19.84%
+94,887
New +$79M
LLY icon
2
PUT
Eli Lilly
LLY
$1.07T
$37.2M 9.41%
+45,000
New +$37.4M
SLNO
3
DELISTED
Soleno Therapeutics
SLNO
$35.6M 9.01%
498,473
+4,049
+0.8% +$197K
VRNA
4
DELISTED
Verona Pharma
VRNA
$34.2M 8.65%
538,488
+283,170
+111% +$16.9M
ITCI
5
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$29M 7.34%
219,719
– –
INSM icon
6
Insmed
INSM
$23.2B
$24.3M 6.15%
318,239
+150,300
+89% +$11.5M
MRUS
7
DELISTED
Merus
MRUS
$17.9M 4.52%
424,640
-39,200
-8% -$1.71M
PTGX icon
8
Protagonist Therapeutics
PTGX
$8.75B
$16.1M 4.09%
333,851
+40,000
+14% +$1.68M
ACLX
9
DELISTED
Arcellx
ACLX
$15M 3.8%
229,085
-700
-0.3% -$47.4K
AZN icon
10
AstraZeneca
AZN
$263B
$14M 3.55%
95,376
– –
BSX icon
11
Boston Scientific
BSX
$65.8B
$13.1M 3.31%
+129,700
New +$13.1M
SLNO
12
PUT
DELISTED
Soleno Therapeutics
SLNO
$9.78M 2.48%
+136,900
New +$6.67M
DGX icon
13
Quest Diagnostics
DGX
$25.1B
$9.6M 2.43%
+56,717
New +$9.32M
ALNY icon
14
Alnylam Pharmaceuticals
ALNY
$36.3B
$7.72M 1.95%
28,600
-27,800
-49% -$7.14M
SLNO
15
CALL
DELISTED
Soleno Therapeutics
SLNO
$7.14M 1.81%
+100,000
New +$4.87M
ARGX icon
16
argenx
ARGX
$57.4B
$6.69M 1.69%
11,311
– –
NUVL
17
DELISTED
Nuvalent
NUVL
$6.44M 1.63%
90,745
-113,300
-56% -$8.86M
SRRK icon
18
Scholar Rock
SRRK
$5.71B
$5.54M 1.4%
+172,185
New +$6.62M
RVMD icon
19
Revolution Medicines
RVMD
$40.2B
$3.68M 0.93%
104,190
-180,000
-63% -$7.31M
RYTM icon
20
Rhythm Pharmaceuticals
RYTM
$7B
$2.65M 0.67%
50,000
– –
SWTX
21
DELISTED
SpringWorks Therapeutics
SWTX
$2.38M 0.6%
53,930
– –
VKTX icon
22
Viking Therapeutics
VKTX
$4.04B
$2.18M 0.55%
90,279
– –
VRDN icon
23
Viridian Therapeutics
VRDN
$2.13B
$2.16M 0.55%
160,000
+60,000
+60% +$1.02M
TGTX icon
24
TG Therapeutics
TGTX
$8.58B
$2.15M 0.54%
54,515
– –
ISRG icon
25
Intuitive Surgical
ISRG
$121B
$1.73M 0.44%
+3,500
New +$1.94M
1
2

Similar funds

MIP
Marietta Investment Partners Milwaukee, Wisconsin $499M AUM 41.06% 1-Year Est. Return
H2CM
H/2 Credit Manager Stamford, Connecticut $500M AUM 24.68% 1-Year Est. Return
HCI
Harraden Circle Investments New York $499M AUM 24.03% 1-Year Est. Return
KCL
KR Capital LP New York City, New York $499M AUM
PPC
Park Place Capital Homewood, Alabama $499M AUM 14.38% 1-Year Est. Return
HIC
Holderness Investments Company Greensboro, North Carolina $498M AUM 34.39% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return
HSG
Helen Stephens Group Fort Worth, Texas $501M AUM 16.23% 1-Year Est. Return

Artia Global Partners's Q1 2025 Portfolio in Review

As of Q1 2025, Artia Global Partners held 48 positions worth $395M, up 41% from $280M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Artia Global Partners deployed $86.6M of net new capital in Q1 2025, opening 11 new positions and adding to 6 existing holdings. Its largest new stake was Eli Lilly: 94,887 shares worth $78.4M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 89% a quarter earlier.

On the sell side, the largest reduction was Nuvalent, an estimated $8.86M trimmed.

  • Artia Global Partners's largest Q1 2025 buy was Eli Lilly: 94,887 shares worth $78.4M.
  • Artia Global Partners added most to Verona Pharma in Q1 2025, an estimated $16.9M increase.
  • Artia Global Partners's biggest Q1 2025 reduction was Nuvalent, cutting an estimated $8.86M.
  • Artia Global Partners fully exited Novo Nordisk in Q1 2025, selling an estimated $17.2M.
  • Artia Global Partners's ten largest holdings make up 76% of its $395M portfolio in Q1 2025.
  • Artia Global Partners opened 11 new positions and closed 13 in Q1 2025.
  • Artia Global Partners's portfolio value rose 41% quarter-over-quarter to $395M.

Based on Artia Global Partners's 13F filing for Q1 2025, filed 15 May 2025.